However, in our study, we found that simultaneous treatment of low dose of DNA-PK-i and PARP-i induces synthetic lethality in a triple-negative breast cancer cell line lacking BRCA1, which is elicited through defects in pre-rRNA biogenesis, but not DNA damage response. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.